Year: 2023

– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update. “The third quarter was marked by strong progress across our first-in-class imipridone pipeline, including continued enrollment in our global Phase 3 ACTION study of ONC201 for the treatment of H3 K27M-mutant diffuse glioma,”...

First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024 Transitioned the BRM Selective inhibitor program to Loxo@Lilly Presented preclinical data demonstrating tumor growth inhibition and favorable safety profiles for Selective EP300 and Selective CBP programs Cash, cash equivalents, and marketable securities of $259.9 million, as of September 30, 2023, provides cash runway into the first half of 2026CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended September 30, 2023. With an initial focus...

MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2023. Third Quarter 2023 Results:Revenue of $572.8 million, up $76.8 million or 15.5% compared to the same period last year. GAAP net income of $1.3 million, compared to net loss of $29.5 million in the same period last year. Adjusted EBITDA of $161.5 million, up $37.5 million or 30.2% compared to the same period last year.“Our strong third quarter results demonstrate our team’s dedication to innovation and efficient execution of our strategy to deliver customer solutions that improve revenues, lower costs and increase patient satisfaction,” said Lee...

Company successfully deploys the ERP to U.S. Regulated Waste and Compliance Services BANNOCKBURN, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) today reported results for the third quarter ended September 30, 2023. Revenues for the third quarter were $653.5 million, a decrease of 5.3% compared to $690.3 million in the third quarter of 2022. Income from operations was $24.2 million compared to $50.6 million in the third quarter of 2022. Net income was $2.0 million, or $0.02 diluted earnings per share, compared to $28.0 million, or $0.30 in the third quarter of 2022. Adjusted income from operations1 was $70.3 million, compared to $92.0 million in the third quarter of 2022. Adjusted diluted earnings per share1 was $0.43 compared to $0.65 in the third quarter of last year. Cash flow from operations for the...

Highlights:COMP360 Phase 3 pivotal program ongoing with expanding European clinical sites Secured up to $285 million private placement financing with $125 million upfront Cash position at September 30, 2023 of $248.0 million Conference call on November 2 at 8:00 am ET (12:00 pm UK)LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2023 and provided an update on recent progress across its business. Kabir Nath, Chief Executive Officer, said, “We continue to make progress in our COMP360 phase 3 program, most recently with the authorization to commence recruitment in a number of European clinical trial sites. Both phase...

MINNEAPOLIS, Nov. 02, 2023 (GLOBE NEWSWIRE) — Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, today announced results for its third quarter ended September 30, 2023.   Third Quarter Summary Net Sales Decreased 5.2%Comparable Store Sales Decreased 4.9% Gross Margin of 64.7%Net Income of $1.8 Million and Adjusted EBITDA of $8.3 MillionDiluted Earnings per Share of $0.04Reduced Long-Term Debt by $10.0 Million in the Third Quarter and $35.4 Million Year-to-Date Management Commentary – Cabell Lolmaugh, CEO “We again displayed the cash flow power of our model as we reduced our debt levels by $10 million during the third quarter of 2023 and by over 75% since the beginning of the year. This was made possible by the steps we’ve taken to effectively drive our...

Third Quarter Revenues from Continuing Operations Totaled $525 Million, an Increase of 8 Percent Over the Prior-Year Quarter Q3 GAAP Operating Income from Continuing Operations of $30 Million Adjusted EBITDA from Continuing Operations in Q3 Totaled $79 million, an Increase of 12 Percent Over the Prior-Year Quarter Credit Agreement Net Leverage Ratio Declined Further, to 4.5x at Quarter-End Full Year 2023 Adjusted EBITDA Guidance Range Increased to Between $282 Million and $289 Million; From Prior Range of $270 Million to $285 MillionPHILADELPHIA, Nov. 02, 2023 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI) today reported third quarter 2023 results. On a U.S. GAAP (“GAAP”) basis, the third quarter of 2023 diluted loss per share from continuing operations was $0.11, after strategic expenses, an accounts receivable...

Significant balance sheet improvement driven by divestiture of commercial business Record high CSB recurring monthly revenue balance driven by strong retention Improved capital efficiency with record revenue payback of 2.0 years Continued innovation in core smart home security markets and rationalization of solar footprint BOCA RATON, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT), the most trusted brand in smart home and small business security, today reported results for the third quarter of 2023. Financial highlights for the third quarter of 2023 are listed below. Except for cash flow measures, prior period amounts have been recast to exclude the commercial business, consistent with continuing operations GAAP presentation following the sale of the commercial business. Variances are on a year-over-year basis unless...

Top-line data from Phase 2 CHAPTER-1 prophylactic study anticipated by YE2023 Participated in an End-of-Phase 2 meeting with the FDA; initiation of global Phase 3 clinical study (RAPIDe-3) anticipated within 1H2024 Cash and cash equivalents of €158 million as of September 30, 2023ZUG, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. “We appreciate the FDA’s ongoing communication and collaboration, including our recent productive End-of-Phase 2 meeting, and anticipate initiating RAPIDe-3, our global Phase 3 on-demand study of PHVS416, within the first half...

DALLAS, Nov. 02, 2023 (GLOBE NEWSWIRE) — CSW Industrials, Inc. (Nasdaq: CSWI or the “Company”) today reported record results for the fiscal 2024 second quarter and first half periods ended September 30, 2023. Fiscal 2024 Second Quarter Highlights (comparisons to fiscal 2023 second quarter)Total revenue increased 7% to a record $203.7 million, of which 5%, or $10.1 million was organic growth, and 1% or $2.4 million was inorganic revenue from acquisitions within the last twelve months Net income attributable to CSWI increased 24% to $30.1 million, compared to $24.3 million Earnings per diluted share (EPS) improved 23% to a record $1.93, compared to $1.57 EBITDA increased 21% to $53.0 million, with margin expansion of 300 bps to 26% Cash flow from operations of $44.7 million, compared to $30.5 million, an increase of...